Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
  • A61K8/20—Halogens; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
  • A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
  • A61K8/24—Phosphorous; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
  • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/60—Sugars; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/67—Vitamins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F13/00—Bandages or dressings; Absorbent pads
  • A61F2013/00361—Plasters
  • A61F2013/00727—Plasters means for wound humidity control
  • A61F2013/00748—Plasters means for wound humidity control with hydrocolloids or superabsorbers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
  • A61Q1/02—Preparations containing skin colorants, e.g. pigments

Definitions

• the invention comprises a cosmetic or dermatological preparation comprising at least one nutrient medium phase for skin cells or corneal cells in combination with an aerogel or hydrogel matrix, containing collagens, chitosans having a degree of acetylation of at least 50% and chondroitin sulfates.
• the invention further comprises cell culture media as aqueous phase in combination with the gelling matrix described above in synergistic use with polyurethanes which are used for physiological wound healing or scar reduction.
• Cell culture media are obtainable from suitable specialist retailers as powder or liquid media and have slightly different compositions depending on the nature of the cells or tissue constituents to be cultivated. Cell culture media are used in liquid form. With a suitable composition, they make it possible to maintain or even multiply microorganisms or cells in culture, i.e., outside the body.
• the ratio of mineral and bioorganic substances of a cell culture medium is slightly variable from cell type to cell type and must be ascertained accurately for optimized survival and growth.
• the composition of the cell culture medium always depends on the requirements of the cells to be grown.
• synthetic media whose ingredients are accurately known on the basis of pure substances, and complex media, whose exact composition may vary and is in part not accurately known.
• Cell culture media comprise, besides water, usually a carbon source and a nitrogen source, phosphate compounds and sulfur compounds, and minerals and, optionally, growth promoters or vitamins.
• compositions of the media are suitable, the cells are able to multiply and produce the factors necessary for survival themselves “in situ”.
• the hornified epidermis forms the protective shield of the skin.
• the skin cells keratinocytes
• epidermal differentiation After division of the cells in the basal layer, the keratinocytes migrate to the skin surface and undergo a number of changes during this, until they form the horny layer (stratum corneum) as dead, flat, anuclear corneocytes, and eventually are desquamated.
• proteins having specific functions. These include, inter alia, keratins, involucrin, filaggrin and transglutaminase.
• geroderma is cosmetically treated primarily with vitamin A derivatives or hydroxy acids which lead, via stimulation of the proliferation of the basal cells in the epidermis, to a thickening of the epidermis and thus smoothing of the skin.
• More recent approaches consist of targeted replacement of the proteins which are absent or present in reduced quantity in dry skin or geroderma, or indirect intervention in the metabolic processes which are disturbed in dry skin or with increasing age, in order to normalize them.
• An example which may be mentioned here is stimulation of collagen synthesis with the aim of reducing wrinkles.
• laminin substances for prolonging the lifetime of skin cells and certain extracts for stimulating epidermal differentiation are employed. However, some of these are pharmacologically active substances with a high potential for side effects.
• the object of the present invention is to provide a preparation with which it is possible for the skin to be able to regenerate itself without displaying unwanted side effects.
• EP 296078 describes the preparation and use of a mixture of collagen, acetylated chitosan with a degree of acetylation of from 10 to a maximum of 40% and glycosylaminoglycan as artificial skin.
• This mixture of biomaterials is used in orthopedics and in plastic surgery, and as reconstitution matrices for the regeneration of nerve, bone and skin tissues, the latter in particular for very severe burns.
• a cosmetic and/or dermatological preparation which comprises a mixture of collagen, acetylated chitosan with a degree of acetylation not exceeding 50% and glycosylaminoglycan achieves the stated objects.
• preparations containing in addition one or more skin cell culture media in which the media is preferably selected from DMEM/HAM's F-12 (1:1) and/or MCDB 153 are to be designated as particularly advantageous.
• At least one compound preferably all, selected from the group of L-cystine, L-glutamine, hypoxanthine, L-glutamic acid, thymidine, glycine, lipoic acid, L-histidine HCl, linoleic acid, L-isoleucine, putrescine 2HCl, NaCl, choline chloride, KCl, putrescine, sodium acetate, vitamin B 12 , Na 2 HPO 4 , biotin, MgCl 2 , calcium pantothenate, CaCl 2 , nicotinamide, glucose, pyridoxine HCl, sodium pyruvate, thiamine HCl, NaHCO 3 , adenine, phenol red, myo-inositol, HEPES, lipoic acid, thymidine, L-alanine, folic acid, L-arginine HCl, riboflavin
• a particularly advantageous combination comprises the linkage of cell-nourishing culture media, preferably media for cultivating skin cultures or corneal cultures of all types with a cellular matrix containing collagens, acetylated chitosans with a degree of acetylation of up to 50%, preferably up to 40%, and chondroitin sulfates.
• This combination alone, mixed with cosmetic preparations or incorporated into polyurethane matrices proves to be extremely efficient in relation to skin regeneration, skin care and wound healing.
• the invention makes it possible to regenerate skin or partial skin from individual cells (dermis and epidermis), to transfer this gel matrix precultured in vitro to damaged tissue for complete skin renewal, and the prevention or reduction of scar tissue associated with wound healing.
• the present invention further provides the ideal environment (matrix) for renewing the skin on topical application.
• EP 296078 The preparation of the matrix is described in EP 296078.
• the disclosure of EP 296078 in its entirety is hereby a constituent of the present invention.
• the preparation of the invention also described as primary microporous or nanoporous matrix, preferably consists of marine collagens selected from the group of type 3, type 1, type 4 and/or type 5 or blends thereof, chitosans, preferably with a molecular weight of from 80 000 D to 1.5 000 000 D, and with a degree of acetylation of from 5% to 50%, blended with a mixture of chondroitin 4- and 6-sulfates, which are employed at 3 to 15% of the initial amount of the collagens.
• the preparation or matrix of the invention can be imagined to be in the form of a microtubular or nanotubular sponge.
• composition of the described molecules On lyophilization, the composition of the described molecules generates a nano- or microsponge (matrix).
• the matrix consists of an aerogel prepared by lyophilization, which is introduced into the aqueous phase(s), active ingredient phases or media phases of a finished cosmetic or dermatological preparations. In this case, it is converted into a hydrogel, or processed as aerogel into a, or together with a, for example, polyurethane matrix or silicone matrix.
• collagen, chitosan and glycosylaminoglycan ingredients of the invention are employed in a balanced ratio to one another, especially as described in EP 296078. This is particularly true because the formation of a micro- or nanotubular aerogel or the retention of this structure in the cosmtic preparation or skin covering takes place only through the specific active ingredients listed according to the invention to one another.
• the stationary biopolymer phase with the disperse phase(s) composed of physiological saline solution, minimal media or complete media is converted into a hydrogel phase.
• the hydrogel phase with the properties according to the invention results with the matrix components of the invention.
• Preferred is a ratio of collagen to chitosan ingredients of 60 to 90% to 40 to 10%, in particular 75-85% to 25-15%.
• Collagens is a designation for a family of long-fiber, linear-colloidal, high molecular weight scleroproteins of the extracellular matrix, which occur in connective tissue (e.g. skin, cartilage, tendons, ligaments, blood vessels), in osseine (the protein-containing base substance of bone) and in dentin together with proteoglycans. They are regarded as the most common animal proteins in terms of quantity, with a proportion of 25-30%.
• a mutual anchoring of the collagen fibers and of the cells is produced by fibronectin, which is able to bind collagen and other constituents of the extracellular matrix, but also becomes attached to receptors on cell surfaces.
• the composition of the collagens may vary depending on the origin. Collagens of types 1 to 14 are known, but only types I-III, V and XI have the described fiber structure.
• the matrix of the invention may be an ingredient of aqueous gels, emulsions of the O/W, W/O/W or W/O type, microemulsions or cosmetic stick products and can thus be marketed for the first time in conventional cosmetic application forms.
• the invention also relates to the preparation in skin coverings, patches, pads, tissues or bandages.
• skin coverings particularly in polyurethane-based wound coverings.
• the matrix can be placed on the wound or the part of skin to be treated.
• the constituents of the matrix of the invention are biological polymers which can, through a specific mixing ratio, be converted into a stable aerogel and even be reconstituted as stable hydrogel. It was possible to show in numerous experiments that this gel matrix produces complete healing skin again from individual skin cells when it is placed appropriately on the wound. Advantages were found and demonstrated experimentally for the formulations of the invention for cell regeneration and proliferation of primary skin cells of the keratinocyte and fibroblast type.
• the process for recovering the constituents of the described matrix consists of adding acetylated chitosan to a collagen/water/optionally cell culture medium solution and subsequently adding glycosylaminoglycan, in particular chondroitin 4- or 6-sulfate.
• the proportions according to the invention of the at least 3 active ingredients of the matrix allow sustained or controlled release of active ingredients such as, for example, Q10, retinol, AHA, etc. and, in addition, optionally reduces the side effects of these agents.
• skin cell culture medium all liquid, powdered or solid media in or on which individual cells can multiply or be cultivated.
• purifying media such as, for example, phosphate-buffered saline solution, minimal maintenance media and so-called complete media, in which cells are healthy and metabolically active.
• Complete media may on the one hand be provided with growth factors from animal sera or so-called synthetic sera substitutes in order to improve the growth of specific cells or make same possible at all.
• media and media blends which support the growth, differentiation or metabolism of the specific cells particularly well.
• composition according to the invention of collagens, chitosans and chondroitin sulfates comprises blending with all purifying, minimal or complete media, but especially complete media which have been composed for culturing skin cells and serve in particular as nutrient media for primary human fibroblasts and keratinocytes and which, as nutrient media, make it possible for the dermis to be regenerated from individual fibroblasts, or for the epidermis to be regenerated from individual keratinocytes.
• the skin cell culture media of the invention are thus particularly suitable for cultivating skin cells.
• the skin cell culture media of the invention which are suitable, in the composition of their individual ingredients, for the following purposes are described: culture of fibroblast cells
• the media of the invention act on keratinocyte/fibroblast mixed cultures and 3-D skin models.
• cosmetic or dermatological preparations containing the mixture according to the invention of biomolecules and skin cell culture media are able in or on the human skin itself to activate or simulate those mechanisms which the skin uses for homeostasis and healthy autopoiesis. It is possible in this connection for mixtures of fibroblast- or keratinocyte-relevant growth media to be employed directly or in suitable vesicle technologies and be used for medical/pharmaceutical purposes and cosmetic purposes.
• so-called serum-free media have proved to be advantageous when the cell fraction of the primary keratinocytes and primary fibroblasts is to be positively influenced in the sense of optimized homeostasis.
• all skin cell culture media are suitable for use in cosmetic preparations.
• Particularly suitable skin cell culture media are those employed in the literature for cultivating skin cells or skin-relevant cells, for treating skin irritations and burns.
• media for cultivating remaining cells after extensive burns show an extremely advantageous effect after application of the topical preparations.
• Skin cell culture media advantageous according to the invention are media which permit neogenesis of fibroblasts or keratinocytes alone or in mixed cultures or reduce the formation and passaging of non-benign cells.
• the skin cell culture media DMEM/HAM's F-12 (1:1) and MCDB 153 are particularly suitable for the use according to the invention in cosmetic preparations.
• DMEM/HAM's F-12 (1:1) has the following composition (data in mg/L): NaCl 6999.5 L-Leucine 59 KCl 311.8 L-Lysine HCl 91.25 Na 2 HPO 4 71 L-Methionine 17.24 NaH 2 PO 4 —H 2 O 62.5 L-Phenylalanine 35.5 MgSO 4 -7H 2 O 100 L-Proline 17.25 MgCl 2 -6H 2 O 61 L-Serine 26.25 CaCl 2 116.61 L-Threonine 53.5 Fe(NO 3 ) 3 -9H 2 O 0.05 L-Tryptophan 9 FeSO 4 -7H 2 O 0.417 L-Tyrosine 38.7 CuSO 4 -5H 2 O 0.00125 L-Valine 52.85 ZnSO 4 -7H 2 O 0.432 Choline chloride 9 D-Glucose 3151 ⁇ -Biotin 0.00365 NaHCO 3 2438 Folic acid 2.65 Na Pyru
• MCDB 153 is employed, according to the reference in the literature Barnes D. and Sato G.; Anal. Biochem 102, 255 [1980], for cultivating human keratinocytes. Further, as minimal medium PBS, phosphate-buffered saline, with pH values of from 3.5 to 8.
• MCDB 153 has the following composition (mg/L): NaCl 7599 Choline chloride 13.96 KCl 111.83 Putrescine 0.1611 Sodium acetate-3H 2 O 500 Vitamin B 12 4.07 Na 2 HPO 4 -7H 2 O 536.2 Biotin 0.0146 MgCl 2 -6H 2 O 122 Calcium pantothenate 0.258 CaCl 2 -2H 2 O 4.411 Nicotinamide 0.03663 Glucose 1081 Pyridoxine HCl 0.06171 Sodium pyruvate 55 Thiamine HCl 0.3373 NaHCO 3 1176 Adenine 24.32 Phenol red 1.317 myo-Inositol 18.02 HEPES 6600 Lipoic acid 0.2063 Thymidine 0.7266 Folic acid 0.79 L-Alanine 8.91 Riboflavin 0.03764 L-Arginine-HCl 210.7 CuSO 4 -5H 2 O 0.0002496 L-Asparagine 15.01 FeSO 4
• DMEM/HAM's F-12 (1:1) and MCDB 153 media are particularly selected and suitable in cosmetic or dermatological preparations for the cultivation of monolayer, two-dimensional and organotypical skin models, and permit the in vitro and ex vivo stimulation or retention of skin-specific biofunctions.
• Solution A Solution B Components (1000x) ⁇ M FeSO 4 -7H 2 O 3000 ZnSO 4 -7H 2 O 3000 CoCl 2 -6H 2 O 1000 CuSO 4 -5H 2 O 10 Na 2 SeO 3 10 AlCl 3 -6H 2 O 5 CrK(SO 4 ) 2 -12H 2 O 1.4 NiCl 3 -6H 2 O 1 MnCl 2 -4H 2 O 1 EDTA.Na 2 -2H 2 O 30000 Polysorbate 80 VG 3820 Insulin human in 0.01 M HCl 86
• the liquid media are usually, according to statements in the literature, prepared by using high-purity, pyrogen-free water, this complies with the WFI quality (water for injection) of Pharmacopeia Europa.
• the liquid media are sterilized by filtration and bottled, the systems and methods of manufacture being such that entry of endotoxins and microbes is substantially precluded.
• the media of the invention show advantageous properties in relation to skin regeneration even if the media compositions are altered, such as, for example, with or without choline chloride, with or without H 2 SeO 3 .
• the skin cell culture media and the mixture of biomolecules (collagen/chitosan/-glycosylaminoglycan) and, optionally, additives are mixed into cosmetic or dermatological preparations to give a proportion of up to 99.9% by weight based on the total mass of the preparation.
• cosmetic or dermatological preparations or matrices topical preparations which are suitable for applying said media to the skin in fine distribution and preferably in a form which can be absorbed through the skin.
• suitable for this purpose are aqueous and hydroalcoholic solutions, sprays, foams, foam aerosols, ointments, aqueous gels, emulsions of the O/W or W/O type, microemulsions, hydrophilic or lipophilic patches or cosmetic stick products.
• Particularly preferably suitable as carrier is an aqueous gel, an O/W emulsion, a W/O/W emulsion or a microemulsion.
• the preparation can also be used for the purposes of the invention in body-cleansing compositions such as, for example, soaps, shower baths, shampoos and the like.
• the cosmetic formulations are in particular hydrogels or emulsions of any type, preferably O/W emulsions.
• lipids known in cosmetics can be employed as oily or lipid phase.
• Preparations of the invention in the form of an emulsion contain one or more emulsifiers.
• emulsifiers may advantageously be chosen from the group of nonionic, anionic, cationic or amphoteric emulsifiers.
• the preparations apart from the aforementioned substances contain optionally the additives customary in cosmetics, for example perfume, dyes, antimicrobial substances, refatting agents, complexing and sequestering agents, pearlescent agents, plant extracts, vitamins, active ingredients, preservatives, bactericides, pigments which have a coloring effect, thickeners, emollient, moisturizing and/or humectant substances, or other usual ingredients of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
• the additives customary in cosmetics for example perfume, dyes, antimicrobial substances, refatting agents, complexing and sequestering agents, pearlescent agents, plant extracts, vitamins, active ingredients, preservatives, bactericides, pigments which have a coloring effect, thickeners, emollient, moisturizing and/or humectant substances, or other usual ingredients of a cosmetic or dermatological formulation such as alcohols, poly
• Suitable preparations are also those which can be employed for professional wound management and wound healing or reduction of surgical scars or the like, such as, for example, polyurethane preparations in combination with chitosan/collagen/chondroitin 6-sulfate sponges or solutions.
• antioxidants are specific active ingredients such as, for example, of antioxidants.
• the added antioxidants are advantageously selected from the group of amino acids (e.g. glycine, lysine, arginine, cysteine, histidine, tyrosine, tryptophan) and derivatives thereof (as salt, ester, ether, sugar, nucleotide, nucleoside, peptide and lipid compound), imidazoles (e.g.
• urocanic acid and derivatives thereof (as salt, ester, ether, sugar, nucleotide, nucleoside, peptide and/or lipid compound), peptides such as D,L-carnosine, D-carnosine, L-carnosine, anserine and derivatives thereof (e.g. as salt, ester, ether, sugar, thiol, nucleotide, nucleoside, peptide and lipid compound), carotenoids, carotenes (e.g. ⁇ -carotene, ⁇ -carotene, ⁇ -lycopene, phytoene,) and derivatives thereof (e.g.
• salt as salt, ester, ether, sugar, nucleotide, nucleoside, peptide and/or lipid compound
• chlorogenic acid and derivatives thereof as salt, ester, ether, sugar, thiol, nucleotide, nucleoside, peptide and/or lipid compound
• aurothioglucose propylthiouracil and other thiols (e.g.
• thioredoxin lipoic acid, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters) and the salts thereof, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and derivatives thereof (as salt, ester, ether, sugar, thiol, nucleotide, nucleoside, peptide and/or lipid compound) and sulfoximine compounds (e.g.
• metal chelators e.g. apoferritin, desferral, lactoferrin, ⁇ -hydroxy fatty acids, palmitic acid, phytic acid
• derivatives thereof as salt, ester, ether, sugar, thiol, nucleotide, nucleoside, peptide and/or lipid compound
• ⁇ -hydroxy acids e.g.
• citric acid citric acid, lactic acid, malic acid
• humic acid bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and derivatives thereof
• unsaturated fatty acids and derivatives thereof e.g. ⁇ -linolenic acid, linoleic acid, oleic acid
• folic acid and derivatives thereof furfurylidenesorbitol and derivatives thereof, ubiquinone, ubiquinol, plastoquinone and derivatives thereof (as salt, ester, ether, sugar, thiol, nucleotide, nucleoside, peptide and lipid compound), vitamin C and derivatives (e.g.
• ascorbyl palmitate Mg ascorbyl phosphate, ascorbyl acetate
• tocopherols and derivatives e.g. vitamin E acetate
• phenolic compounds and plant extracts containing same such as, for example, flavonoids (e.g.
• glycosylrutin, ferulic acid, caffeic acid furfurylideneglucitol, butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguaiaretic resin acid, nordihy-droguaiaretic acid, trihydroxybutyrophenone and derivatives thereof (as salt, ester, ether, sugar, nucleotide, nucleoside, peptide and lipid compound), uric acid and derivatives thereof, mannose and derivatives thereof (as salt, ester, ether, sugar, thiol, nucleotide, nucleoside, peptide and lipid compound), zinc and its derivatives (e.g.
• ZnO, ZnSO 4 selenium and its derivatives (e.g. selenomethionine, ebselen), stilbenes and derivatives thereof (e.g. stilbene oxide, trans-stilbene oxide) and the derivatives suitable according to the invention (as salt, ester, ether, sugar, thiol, nucleotide, nucleoside, peptide and/or lipid compound) of these active ingredients mentioned.
• Phosphate-buffered saline solutions or citrate buffers are preferably employed in this case.
• antioxidants or from the group thereof, combinations of the preparations of the invention with specific ingredients which are preferably chosen from the group of Q10, AGR, Zn orotrate, carnitine, creatine and/or taurine are favored.
• Areas of application of the preparation of the invention which have proved to be particularly advantageous are the care of all skin types with the exception of all septic inflammations, also special applications such as microdermal abrasion, acid peeling and retinol treatments.
• the skin regeneration and soothing of the skin by the preparations of the invention is detectable in these cases.
• cosmetic care of the skin in particular for beautification.
• the packaging can include all cosmetically customary dosage systems such as, for example, jars, pump bottles, pipette bottles, cartridges or capsules.
• the cell culture media For problematic formulations into which the cell medium cannot be incorporated, it would be possible to mix the cell culture media and cosmetic product only before use, through special packaging elements such as, for example, double cartridges with mixing head as known, for example, from 2-component adhesives.
• the packaging of the cell culture medium might also be designed for refilling, so that only fresh product is used.
• polyurethane matrices It is advantageous to incorporate the matrix of the invention in polyurethane matrices and configure them as cosmetic skin covering, wound covering in plasters or bandages or as pad.
• Possible polyurethane matrices which should be mentioned in particular are those from the publications DE 42 33 289, DE 43 08 347, DE 43 08 445, DE 43 28 190 and DE 101 28 685, which are hereby included in the disclosure of the present invention.
• the quantitative data are always based on weight % as long as nothing contrary is indicated. It is possible in all the preparations for the ratio described above of the matrix molecules collagen, chitosan and glycosylaminoglycan to be from 0.00001% by weight to 99% by weight of the final formulation, preferably 0.0005% by weight to 50% by weight and ideally 0.0015 to 30% by weight, based on the total mass of the preparation.
• the dispersant “culture medium” should correspond to an osmotic pressure of a 0.5 to 2% sodium chloride solution, but ideally correspond to the physiological osmotic pressure of human tissue, especially of the skin.
• HISTIDINE, GLUCOSE and CALCIUM CHLORIDE therein are the components of the aqueous phase which serves as disperse phase.
• KERATINOCYTE MEDIUM MCDB153 40% by weight COLLAGEN/CHITOSAN/CHONDROITIN SULFATE 6% by weight matrix and blended in any proportion WATER (AQUA) GLYCERIN HYDROGENATED COCO-GLYCERIDES SQUALANE GLYCERYL STEARATE CITRATE CAPRYLIC/CAPRIC TRIGLYCERIDE ETHYLHEXYL COCOATE MYRISTYL ALCOHOL BUTYROSPERMUM PARKII (SHEA BUTTER) BUTYLENE GLYCOL CETYL ALCOHOL TOCOPHERYL ACETATE PHENOXYETHANOL SODIUM CHLORIDE IMIDAZOLIDINYL UREA CARBOMER XANTHAN GUM METHYLPARABEN EDTA SODIUM HYDROXIDE BHT ETHYLPARABEN BUTYLPARABEN ISOBUTYLPARABEN PROPYLPARABEN
• the fatty phase containing the emulsifier is heated to 80° C., likewise the aqueous phase without that proportion that contains the medium.
• the two phases are combined at 80° C., homogenized for about 3-10 minutes and then cooled to 48° C. or room temperature. Then, keeping the temperature constant to ⁇ 1° C., the proportion of water with medium is added and mixed.
• Glyceryl stearate citrate 3.00
• Stearyl alcohol 1.00
• Octyldodecanol 1.00
• Caprylic/capric triglyceride 1.00
• Dicaprylyl ether 1.00
• Carbomer 0.15
• Glycerin 3.00 Perfume, preservative, NaOH q.s. dyes, antioxidants, etc.
• Collagen/chitosan/glycosylaminoglycan matrix 4.0% Water ad 100.00 of which DMEM/HAM's F-12 (1:1) 2.5% pH adjusted to 5.5
• Glyceryl stearate citrate 3.00 Cetyl alcohol 0.50 Octyldodecanol 0.40 Caprylic/capric triglyceride 0.40 Dicaprylyl ether 0.40 Carbomer 0.10 Glycerin 3.00 Serine 0.50% Collagen/chitosan/glycosylaminoglycan matrix 1.2% Perfume, preservative, NaOH q.s. dyes, antioxidants etc. Water ad 100.00 of which MCDB 153 45.5% pH adjusted to 5.5
• Glyceryl stearate citrate 3.00
• Stearyl alcohol 1.00 Octyldodecanol 0.25
• Caprylic/capric triglyceride 0.25
• Dicaprylyl ether 0.25
• Benzophenone-3 3.00
• Octyl salicylate 3.00
• Carbomer 0.15
• Glycerin 3.0
• Collagen/chitosan/glycosylaminoglycan matrix 1.75 Perfume, preservative, NaOH q.s. dyes, antioxidants etc. Water ad 100.00 of which MCDB 153 40% pH adjusted to 5.5
• Glyceryl stearate citrate 3.00 Stearyl alcohol 1.00 Ethanol 2.00 Aluminum starch octenyl succinate 0.25 Talc 0.25 Tapioca starch 0.25 Carbomer 0.15 Glycerin 3.00 Collagen/chitosan/glycosylaminoglycan matrix 0.10 Perfume, preservative, NaOH q.s. dyes, antioxidants etc. Water ad 100.00 of which DMEM/HAM's F-12 (1:1) 3.5% pH adjusted to 5.5

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Birds (AREA)
• Chemical & Material Sciences (AREA)
• Inorganic Chemistry (AREA)
• Dermatology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Cosmetics (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (1)

Applications Claiming Priority (7)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=33479380

Family Applications (3)

Family Applications After (2)

Country Status (4)

Cited By (18)

Families Citing this family (23)

Citations (47)

Family Cites Families (25)

• 2004
  • 2004-05-22 EP EP04734472A patent/EP1635782A1/de not_active Ceased
  • 2004-05-22 WO PCT/EP2004/005532 patent/WO2004103333A1/de active Application Filing
  • 2004-05-22 JP JP2006529900A patent/JP2007500196A/ja active Pending
  • 2004-05-22 EP EP04078585.9A patent/EP2340856B2/de not_active Expired - Lifetime
  • 2004-05-22 EP EP04734469A patent/EP1896092A1/de active Pending
  • 2004-10-19 US US10/967,232 patent/US20050249691A1/en not_active Abandoned
• 2005
  • 2005-03-01 US US11/068,052 patent/US8518422B2/en active Active
  • 2005-11-23 US US11/285,342 patent/US8507276B2/en not_active Expired - Fee Related

Patent Citations (57)

Also Published As

Similar Documents

Legal Events